NYSE · DGX
Healthcare · Medical - Diagnostics & Research
$230.97
Up+$0.16 (+0.07%)
Updated Oct 11, 2026, 2:35 AM
SID Score
6.4/10
Composite research score
Smart Money
47/100
Neutral
Price performance · DGX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
DGX closed at $230.97 after 20 trading sessions, down 2.91% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $227.86 | $232.18 | $227.86 | $230.97 | 775.46K |
| Oct 8, 2026 | $228.16 | $231.08 | $226.36 | $230.81 | 941.88K |
| Oct 7, 2026 | $228.51 | $229.80 | $226.81 | $227.06 | 927.43K |
| Oct 6, 2026 | $229.92 | $232.09 | $225.78 | $228.39 | 1.78M |
| Oct 5, 2026 | $232.93 | $233.65 | $229.955 | $232.22 | 1.01M |
| Oct 2, 2026 | $230.58 | $233.48 | $228.83 | $233.33 | 1.1M |
| Oct 1, 2026 | $232.74 | $233.33 | $230.47 | $231.09 | 992.18K |
| Sep 30, 2026 | $233.33 | $236.965 | $230.84 | $233.07 | 1.09M |
| Sep 29, 2026 | $235.46 | $237.62 | $230.975 | $231.97 | 1.54M |
| Sep 28, 2026 | $234.27 | $238.104 | $233.8101 | $237.62 | 1.04M |
| Sep 25, 2026 | $236.37 | $238.245 | $235.48 | $236.32 | 741.73K |
| Sep 24, 2026 | $234.08 | $237.29 | $233.55 | $236.59 | 926.9K |
| Sep 23, 2026 | $235.12 | $238.62 | $231.9225 | $233.00 | 1.13M |
| Sep 22, 2026 | $228.59 | $237.285 | $227.24 | $234.76 | 2.72M |
| Sep 21, 2026 | $247.13 | $248.84 | $243.93 | $244.88 | 907.61K |
| Sep 18, 2026 | $246.52 | $247.625 | $244.89 | $246.45 | 1.93M |
| Sep 17, 2026 | $248.28 | $248.695 | $246.26 | $247.45 | 989.5K |
| Sep 16, 2026 | $245.47 | $248.57 | $244.85 | $247.08 | 948.75K |
| Sep 15, 2026 | $238.39 | $248.65 | $237.21 | $247.08 | 1.37M |
| Sep 14, 2026 | $237.49 | $239.78 | $234.67 | $237.89 | 974.85K |
The latest Smart Investors Daily articles mentioning DGX.
Company
Market Activity
Research & News
DGX research
Company profile and research snapshot.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Overweight | — |
| Sep 21, 2026 | Truist Securities | Hold | — |
| Sep 8, 2026 | UBS | Neutral | — |
| Jul 28, 2026 | JP Morgan | Neutral | — |
| Jul 24, 2026 | Barclays | Overweight | — |
No generated briefing is available yet.
ChartMill · Oct 9, 2026
Quest Diagnostics (DGX) clears ChartMill's Best Dividend screen with a 2.1% yield, strong profitability, safe payout, and 10+ years of dividend growth.
Yahoo · Oct 8, 2026
Oracle director Stephen Rusckowski bought 25,000 shares as reports about OpenAI’s revenue fueled swings in the cloud provider’s stock.
Benzinga · Oct 7, 2026
Barclays analyst Luke Sergott maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $250 to $260.
Yahoo · Oct 5, 2026
Quest Diagnostics is set to report its Q3 earnings next month, with analysts expecting single-digit year-over-year EPS growth.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DGX.
